Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma
Autor: | Daniele Generali, Navid Sobhani, Fabrizio Zanconati, Fabiola Giudici, Marco Confalonieri, Silvia Paola Corona, Deborah Bonazza, Giandomenico Roviello, M. Cortale, M. Milione, A. Guglielmi, Cristina Bottin, Anna Ianza, T. Pivetta, Clara Rizzardi |
---|---|
Přispěvatelé: | Sobhani, N, Roviello, G, Pivetta, T, Ianza, A, Bonazza, D, Zanconati, F, Giudici, F, Bottin, C, Corona, Sp, Guglielmi, A, Rizzardi, C, Milione, M, Cortale, M, Confalonieri, M, Generali, D. |
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Oncology Male Mesothelioma Immunotherapy Malignant pleural mesothelioma Programmed cell death-ligand 1 Tumour-infiltrating lymphocytes Lung Neoplasms Survival medicine.medical_treatment Kaplan-Meier Estimate Clinical-Trial B7-H1 Antigen 0302 clinical medicine Cancer Phase-III Aged 80 and over General Medicine Middle Aged Prognosis Immunohistochemistry Treatment Outcome 030220 oncology & carcinogenesis Pd l1 expression Female Adult medicine.medical_specialty Pleural Neoplasms T-Cells chemical and pharmacologic phenomena Neoadjuvant chemotherapy Programmed cell death ligand 1 03 medical and health sciences Lymphocytes Tumor-Infiltrating Stroma Internal medicine Statistical significance Genetics medicine Biomarkers Tumor Humans In patient Molecular Biology Aged Retrospective Studies Pleural mesothelioma business.industry Tumour-infiltrating lymphocyte Mesothelioma Malignant medicine.disease T-Cell 030104 developmental biology business Transcriptome |
Zdroj: | Molecular biology reports. 46(3) |
ISSN: | 1573-4978 |
Popis: | Malignant pleural mesothelioma (MPM) is a rare and aggressive form of tumour. Some mesotheliomas have been proven to be highly immunogenic. Here, we investigated the correlation between tumour infiltrating lymphocytes (TILs) or programmed cell death ligand 1 (PD-L1) expression with overall survival (OS) in patients with MPM. 62 Paraffin-embedded formalin fixed (PEFF) samples were analysed for TILs and PD-L1 expression. Patients were divided in 4 groups according to a cut-off of the percentage of TILs found per sample as measured by immunohistichemistry: “0” or absent (between 0 and 5%), “1” or low (between 6 and 25%), “2” or moderate (between 26 and 50%) and “3” or high (between 51 and 75%). OS was then correlated with different TILs’ expression patterns. Moreover, PD-L1 expression was assessed within the tumour as well as in the adjacent stroma on the same samples. Higher expression of peritumoral TILs (Group 2 + 3) versus Group 0 and 1 correlated with improved OS (p-value = 0.02). On the contrary PD-L1 expression seemed to be inversely correlated with clinical outcomes, even in the absence of statistical significance (HR 1.76; p = 0.083 95% IC 0.92–3.36 in areas within the tumour; HR 1.60; p = 0.176 95%; IC 0.80–3.19 in areas within the stroma). No relationship between TILs and PD-L1 expression was identified. Our research supports the use of TILs and PD-L1 expression as potential outcome predictors in patients with MPM. The use of TILs and PD-L1 as biomarkers for checkpoint inhibitors’ efficacy warrants future investigation. |
Databáze: | OpenAIRE |
Externí odkaz: |